NITE - Nightstar Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.81
-0.65 (-5.22%)
At close: 4:00PM EST

11.89 +0.08 (0.68%)
After hours: 4:02PM EST

Stock chart is not supported by your current browser
Previous Close12.46
Open12.42
Bid11.89 x 800
Ask11.89 x 1200
Day's Range10.63 - 13.99
52 Week Range9.59 - 29.55
Volume322,618
Avg. Volume151,446
Market Cap395.447M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.50
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Nightstar Therapeutics to Participate in Multiple Conferences in November

    WALTHAM, Mass. and LONDON, Nov. 08, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal.

  • GlobeNewswire20 days ago

    Report: Exploring Fundamental Drivers Behind Corcept Therapeutics, News Corporation, Nightstar Therapeutics PLC Sponsored ADR, Rudolph Technologies, Applied Optoelectronics, and United Rentals — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference

    WALTHAM, Mass. and LONDON, Oct. 04, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal.

  • GlobeNewswirelast month

    Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option

    Nightstar Therapeutics plc (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the closing of its underwritten public offering of 4,600,000 American Depositary Shares (“ADSs”) representing 4,600,000 ordinary shares, at a public offering price of $18.00 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 ADSs. The aggregate gross proceeds to Nightstar from the offering were $82.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Nightstar. All ADSs sold in the offering were offered by Nightstar.

  • GlobeNewswirelast month

    Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa

    WALTHAM, Mass. and LONDON, Oct. 01, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal.

  • GlobeNewswire2 months ago

    Nightstar Announces Pricing of Public Offering

    Nightstar Therapeutics plc (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of an underwritten public offering of 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares, at a public offering price of $18.00 per ADS, for total gross proceeds of $72 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Nightstar. All ADSs to be sold in the offering are being offered by Nightstar. In addition, Nightstar has granted the underwriters an option for a period of 30 days to purchase up to an additional 600,000 ADSs on the same terms and conditions.

  • GlobeNewswire2 months ago

    Nightstar Announces Proposed Public Offering of American Depositary Shares

    Nightstar Therapeutics plc (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that it has commenced an underwritten public offering of 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares. In addition, Nightstar expects to grant the underwriters an option for a period of 30 days to purchase up to an additional 600,000 ADSs on the same terms and conditions. All ADSs to be sold in the offering will be offered by Nightstar.

  • Benzinga2 months ago

    Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update

    The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC ), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an ...

  • GlobeNewswire2 months ago

    Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients

    Nightstar Therapeutics plc (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress. “We initiated this study last year, with the anticipation of demonstrating safety and stabilization of disease with NSR-RPGR, our codon-optimized gene therapy for XLRP,” said Tuyen Ong, M.D., chief development officer of Nightstar.

  • GlobeNewswire2 months ago

    Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors

    “We are very happy to welcome Paula to our board of directors and working alongside the very strong team we have built at Nightstar,” said David Fellows, chief executive officer of Nightstar. Ms. Cobb currently serves as the executive vice president of corporate development at Decibel Therapeutics, Inc. Prior to joining Decibel, she served as senior vice president of the rare disease group at Biogen, where she was responsible for the company’s marketed hemophilia assets and Phase 3 programs in spinal muscular atrophy and neuropathic pain.

  • Play The Future of Gene Therapy With These 5 Biotech Stocks
    InvestorPlace3 months ago

    Play The Future of Gene Therapy With These 5 Biotech Stocks

    Innovation has always been the mantra when it comes to biotech stocks. Gene therapy is quickly becoming the technique du jour for curing orphan and rare diseases. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight the faulty ones, replacing/editing missing/broken prices or actually “turning off” the genes causing problems.

  • Benzinga3 months ago

    Janney: Nightstar Therapeutics Has 'Significant Upside Potential' With Retinal Disorder Treatments

    Nightstar retains close ties with the University of Oxford, which provides academic expertise as well as strong results from prior studies and the preclinical development of two new programs, Zhong said in the initiation note.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks keep the momentum going?

  • Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher
    Zacks4 months ago

    Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher

    Nightstar Therapeutics (NITE) was a big mover last session, as the company saw its shares rise more than 6% on the day.

  • InvestorPlace6 months ago

    A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future

    While steady growth is appreciated by some investors, that’s not that great overall and doesn’t necessarily support its constant valuation premium. To that end, Johnson & Johnson needs to find some serious growth to keep investors coming back to its shares. Vision care is quickly becoming a major growth engine for JNJ.

  • Newsfile8 months ago

    CSE New Listing - Cryptanite Blockchain Technologies Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - March 15, 2018) - Cryptanite Blockchain Technologies (CSE: NITE) one of the latest new listings on the Canadian Securities Exchange, trading under the symbol "NITE", having previously traded on the TSX Venture Exchange as Westbay Ventures (TSXV: WEST). The company acquired 100% of ChargaCard by issuing approximately 39.5 million shares to the shareholders of ChargaCard.InvestmentPitch Media has produced a "video" which provides a brief overview of the company. If ...